Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Novo Nordisk CEO spars with lawmakers over Ozempic, Wegovy prices
The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers pressed the Danish pharmaceutical giant to cut the prices of its blockbuster diabetes and obesity medications.
'Stop ripping us off,' says Sen. Sanders, but Novo CEO blames PBMs for high Wegovy prices
Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal blood sugar.
Novo Nordisk CEO grilled by Congress over Ozempic, Wegovy prices in US
For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their health.
Sanders leads HELP Committee hearing with Novo Nordisk CEO on Ozempic and Wegovy prices
Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to examine why Novo Nordisk charges the American people the highest prices in the world for its lifesaving drugs,
Novo Nordisk CEO Stands by Drug Pricing of Ozempic, Wegovy
Novo Nordisk Chief Executive Lars Jorgensen challenged Medicare's new role negotiating prescription drug prices during his testimony before a Senate committee on the company's blockbuster diabetes and weight-loss drugs.
Ozempic, Wegovy maker Novo Nordisk questioned over high cost of weight-loss drugs
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North Carolina cut the weight-loss drugs from its state health plan.
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
Ozempic maker's CEO grilled over price of weight loss drugs
The CEO of the company that makes Ozempic faced a Bernie Sanders-led Senate hearing on Tuesday.
Novo Nordisk CEO Faces Senate Questions Over High Prices Of Ozempic And Wegovy In US
Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in
54m
Novo Nordisk’s Wegovy-Fueled Gains Fading as Analyst Doubts Grow
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much ...
2d
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
15h
RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
STAT
2d
Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...
c-span
3d
Novo Nordisk CEO Testifies on Ozempic & Wegovy Prices
as
Novo
Nordisk
CEO Lars Jergensen testified on the company’s pricing for its diabetes and weight loss drugs, Ozempic and
Wegovy
, respectively. Mr. Jergensen answered questions on a variety of ...
In Depth
1d
In Depth
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
1d
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ozempic
United States
Lars Fruergaard Jorgensen
European Medicines Agency
Feedback